Oncotarget and Mikhail Blagosklonny

Oncotarget is a medical journal that widely covers oncology, A branch of medicine that deals with the analysis, treatment, and prevention of Cancer. The medical journal was established in 2010 and published by Impact Journals.

Andrei V.Gudkov and Mikhail Blagosklonny, the pioneer chief editors of the journal; the two editors are based at Rosewell Parks Cancer Institute. Oncortaget is significantly helpful because it offers resources like the scientific research and results. It helps people have a better understanding of how to handle and fight the disease. Oncortaget was ranked number one in 2015 among the oncology journals in the United States. Visit classroomvoices.org to read more about Mikhail.

The Main aim of Oncotarget is to emerge an exceptional example in scientific researchers in oncology. On the same note but the different perspective one of the research papers that was published and developed as unique as a success of the journal called the impact of HuR impediment by the small molecule MS-444 on collateral cancer cell tumorigenesis.

Cancer is a deadly disease, and its branch collateral cancer is ranked third as the most common cancer that causes death. Oncotarget is a platform that allows people interact and give in their ideas and thus solutions are generated from there.

The research carried out showcases apparently those therapeutic findings targets HuR in CRC guarantees significant results. On the same token, Oncotarget medical journal plays a vital role in helping the people to understand oncology better. The cancer research paper provides more information on the treatment and prevention. live your life healthy. View his LinkedIn profile

Comments are Disabled